Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Retirement Systems of Alabama

Retirement Systems of Alabama lessened its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 8.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 719,464 shares of the medical equipment provider’s stock after selling 63,634 shares during the quarter. Retirement Systems of Alabama owned 0.32% of Hologic worth $58,608,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of HOLX. FMR LLC lifted its stake in shares of Hologic by 64.0% in the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after acquiring an additional 2,174,093 shares in the last quarter. Black Creek Investment Management Inc. boosted its stake in shares of Hologic by 60.9% during the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after buying an additional 885,524 shares during the last quarter. Mackenzie Financial Corp boosted its stake in shares of Hologic by 1,023.3% during the 2nd quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock valued at $66,506,000 after buying an additional 815,960 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Hologic during the second quarter worth approximately $39,427,000. Finally, The Manufacturers Life Insurance Company raised its holdings in Hologic by 21.6% in the second quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider’s stock valued at $188,243,000 after acquiring an additional 450,190 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Insider Buying and Selling at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.75% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

HOLX has been the subject of a number of research reports. UBS Group lifted their price target on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Mizuho lowered their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. Leerink Partners dropped their price objective on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Finally, Citigroup cut Hologic from a “buy” rating to a “neutral” rating and cut their price target for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Six equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $89.50.

Hologic Price Performance

HOLX stock traded down $0.64 during trading hours on Friday, hitting $74.45. 64,280 shares of the stock traded hands, compared to its average volume of 1,616,276. The stock has a 50-day simple moving average of $79.45 and a 200 day simple moving average of $78.56. The company has a market cap of $16.90 billion, a P/E ratio of 22.55, a P/E/G ratio of 2.38 and a beta of 0.96. Hologic, Inc. has a one year low of $70.24 and a one year high of $84.67. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. During the same quarter in the previous year, the company posted $0.89 EPS. The business’s revenue was up 4.5% compared to the same quarter last year. Equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.